NCT01077024

Smoking-Cessation and Stimulant Treatment (S-CAST)

Smoking-Cessation and Stimulant Treatment (S-CAST): Evaluation of the Impact of Concurrent Outpatient Smoking-Cessation and Stimulant Treatment on Stimulant-Dependence Outcomes

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 538 (actual)
• Sponsor: University of Cincinnati · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of this study is to evaluate the impact of substance-abuse treatment as usual plus smoking-cessation treatment (TAU+SCT), relative to substance-abuse treatment as usual (TAU), on drug-abuse outcomes. Specifically, this study will evaluate whether concurrent smoking-cessation treatment improves, worsens, or has no effect on stimulant-use outcomes in smokers who are in outpatient substance-abuse treatment for cocaine or methamphetamine dependence.

Conditions

• Cocaine Dependence
• Methamphetamine Dependence
• Nicotine Dependence

Interventions

Type	Name	Description
OTHER	Smoking-cessation treatment	Smoking cessation treatment includes four components: 1. brief weekly individual smoking-cessation counseling study weeks 1-10; 2. extended-release (XL) bupropion (300 mg/day)study weeks 1-10; 3. nicotine inhaler (6-16 cartridges per day ad libitum)during the post-quit treatment phase; 4. prize-based contingency management during the post-quit treatment phase.

Timeline

• Start date: 2010-02-01
• Primary completion: 2012-08-01
• Completion: 2012-08-01
• First posted: 2010-02-26
• Last updated: 2021-09-29
• Results posted: 2014-08-20

Locations

12 sites across 1 country: United States